The purpose of the present study was to determine whether peripheral blood lymphocytes (PBL) from primary open angle glaucoma (POAG) patients have reduced 3α-hydroxysteroid dehydrogenase (3α-HSD) activity as was previously found in POAG-derived cultured trabecular meshwork cells. The availability of PBL from both POAG and control patients makes this a useful system for studying the association of decreased 3α-HSD activity with POAG.
Introduction
In normal mammalian tissues, cortisol is metabolized primarily by cortisol-∆%-reductases to the dihydrocortisols (5α-DHF and 5β-DHF) and then by 3α-hydroxysteroid dehydrogenase (3α-HSD) to the 3α-tetrahydrocortisols. The enzyme 3α-HSD is found in many ocular (Iyer et al., 1993) and extra-ocular tissues and can reduce a variety of substrates such as 3-ketosteroids (Tomkins G. M., 1956 ; Gustafsson et al., 1983) , bile acids (Takikawa et al., 1990) , prostaglandins (Penning and Sharp, 1987) and xenobiotics (Smithgall et al., 1986) . Hepatic 3α-HSD has been purified from many species (Ikeda et al., 1984 ; Penning et al., 1984 ; Worner and Oesch, 1984 ; Hara et al., 1988 ; Morikawa and Amaoki, 1990) including the human (Kudo et al., 1990 ; Iyer et al., 1992 ; Takikawa et al., 1992) .
3α,5β-Tetrahydrocortisol (3α,5β-THF) is the major glucocorticoid metabolite in humans and is conjugated with glucuronide and ultimately excreted in the urine * For correspondence at : Department of Biochemistry & Molecular Biology, New York Medical College, Valhalla, NY 10595, U.S.A. (Cope, 1972) . Cortisol and other steroid hormones are present in the aqueous humor of many species, including human (Starka et al., 1976 (Starka et al., , 1977a (Starka et al., , 1977b Rozsival et al., 1981 ; Weinstein et al., 1991) . Human trabecular meshwork (HTM) cells cultured from POAG patients were previously shown to metabolize cortisol at a much greater rate than control nonglaucoma derived cells with the major products being 5β-DHF (80 %) and 5α-DHF (20 %), intermediates not seen in control cells . The POAG derived cells did not produce any THF. This change in cortisol metabolism in POAG derived HTM cells was later shown to be due to an increase in cortisol-∆%-reductase activity and a decrease in 3α-HSD activity . In these previous reports, HTM cells were assayed for both cortisol-∆%-reductase and 3α-HSD, and at that time PBL were assayed only for cortisol-∆%-reductase which was found to be unchanged in POAG derived PBL.
The biologic activities of these cortisol metabolites, however, were not known. 5β-DHF was subsequently found to potentiate many glucocorticoid effects including the elevation in intraocular pressure (IOP) Southren et al., 1985 ; Southren et al., 1986) , and its accumulation in POAG 0014-4835\96\010039j07 $12.00\0
# 1996 Academic Press Limited tissue may be the basis for the steroid sensitivity and ocular hypertension seen in many POAG patients. The finding of the ocularly hypotensive activity of 3α,5β-THF in rabbits made ocularly hypertensive with glucocorticoids (Southren et al., 1987 and Clark et al., 1994) and in POAG patients (Southren et al., 1994) , led us to now assay 3α-HSD activity in the readily obtainable PBL from POAG and non-glaucoma patients since this enzyme converts the ocularly hypertensive 5β-DHF to the hypotensive 3α,5β-THF. While a decrease in 3α-HSD activity in the HTM of POAG patients is more directly related to the etiology of the disorder, a decrease in this activity in PBL may reflect a similar decrease in the ocular enzyme. In addition, the present study examines the relationship between PBL 3α-HSD activity and its protein expression in order to determine whether the decrease in 3α-HSD activity is the result of a decreased amount of enzyme.
Materials and Methods

Diagnostic Groups
The POAG group consisted of 17 genetically unrelated patients with a history of elevated IOP ( 26 mmHg), open angles on gonioscopy, optic nerve cup to disk ratios 0n7 and characteristic visual field loss. Patients with pseudoexfoliation or pigmentary dispersion syndromes were not included. The control group consisted of 22 genetically unrelated nonglaucoma patients with no family history of glaucoma. They had ocular exams within the past year which revealed no indication of elevated IOP or optic nerve disease. The research followed the tenets of the Declaration of Helsinki and informed consent approved by the New York Medical College Institutional Review Board was obtained from all subjects.
Peripheral blood lymphocytes
To minimize possible diurnal variations, venous blood samples were all collected between 0800 and 1200 hr. No subject had any surgical or laser procedure, or steroid medication for 2 weeks prior to blood collection. The anticoagulant EDTA was used and the samples processed within 4 hr of collection. Nearly identical values of PBL 3α-HSD activity were obtained from two samples of the same blood in which one was used immediately and the other left at room temperature for 4 hr before processing. Two volumes of RPMI 1640 medium (Gibco BRL) were added to 1 volume of blood which was then layered on FicollPaque Research Grade (density l 1n077 g ml −" ; Pharmacia) and centrifuged for 20 min at 1200 g. The mononuclear leukocyte layer was removed and washed three times with RPMI medium and resuspended in the same medium (Boyum, 1977) . This preparation contains 90 % lymphocytes with 10 % other cells (mononucleocytes, granulocytes and erythrocytes). An aliquot was mixed with an equalvolume of Trypan blue for counting with a hemacytometer. Viability, as determined by dye exclusion, was 90 %. The PBL suspension was adjusted to 5-10i10' cells ml −" and incubated with substrate as described below.
3α-Hydroxysteroid Dehydrogenase Activity
[1,2-$H]-5β-DHF (specific activity 55 Ci mmol −" ) was prepared and purified from $H-cortisol as described previously (Iyer et al., 1990) . PBL were incubated with 0n05 µmCi $H-5β-DHF in 0n5 ml of Hepes buffered RPMI medium supplemented with penicillin Gstreptomycin-Fungizone (100 U, 100 µg and 0n25 µg ml −" respectively) at 37mC. After incubation, the steroids were extracted from the medium with ethylacetate (twice), evaporated to dryness, separated by thin layer chromatography and quantified as described previously . Measurements of 3α-HSD activity in PBL were performed in duplicate and the average reported. The duplicates did not vary by more than 10 %. With several specimens, the product of the incubation was identified as 3α,5β-THF by HPLC (Iyer et al., 1990) . One Unit (U) of 3α-HSD activity is equal to 10 −& nmol 3α,5β-THF formed\5i10' cells hr −" at 37mC.
Immunoblot Analysis
Homogenates of PBL were prepared in 50 m phosphate buffer (pH 7n4) containing 1 % NP40 using a Teflon homogenizer and centrifuged at 1500 g to remove debris. An aliquot of the supernatant (75 or 100 µg protein) was electrophoresed in the presence of SDS (0n75 mm thick 10 % polyacrylamide slab gels) (Laemmli, 1970) . Immunoblot assay was performed with an enhanced chemiluminescence kit as previously described ) using a Protein-A purified anti-3α-HSD polyclonal antibody prepared as described below.
Preparation of Anti-3α-HSD Antibody
Purified human hepatic 3α-HSD was electrophoresed in SDS polyacrylamide gels. Slices from the SDS gels containing 20 µg of 3α-HSD were suspended in 1 ml phosphate buffered saline, homogenized with an equal volume of Freund's complete adjuvant and injected subcutaneously in multiple sites of each of two rabbits. The rabbits received two booster injections of 20 µg each of 3α-HSD homogenized with Freund's incomplete adjuvant at 1 month intervals and were terminally bled 3 weeks after the second booster injection. The sera were purified on a Protein-A column to isolate the immunoglobulin fraction containing antibodies. This preparation containing anti-human 3α-HSD antibody was used for immunoblot analysis. Similarly purified preimmune serum was used as a control. Ocular medications : 1a, β1 adrenergic receptor antagonist ; 1b, β1, β2 adrenergic receptor antagonist ; 2, sympathomimetic ; 3, parasympathomimetic ; 4, oral carbonic anhydrase inhibitor ; 5, osmotic agent.
Non-ocular medications : 1a, β1 adrenergic receptor antagonist ; 1b, β1, β2 adrenergic receptor antagonist ; 2, coronary vasodilator ; 3, ACE inhibitor ; 4, CNS agent ; 5, anticoagulant ; 6, cholesterol lowering agent ; 7, diuretic ; 9, thyroid hormone ; 11, calcium channel antagonist ; 12, hypoglycemic agent ; 13, bronchodilator ; 14, uricosuric agent ; 15, analgesic\anti-inflammatory agent ; 16, histamine antagonist.
Quantitative Analysis of Immunoblots
The 3α-HSD-immunoreactive protein in PBL homogenates was quantified by volume integration of Hyperfilm-ECL images with an optical imaging system (Jandel Scientific). The optical density of each band was averaged over a constant predetermined area and expressed on a relative densitometric scale ranging from 0 to 100 O.D. units (Huang et al., 1994) .
Analysis of dilutions of PBL homogenates from both POAG and non-glaucoma patients showed essentially identical linear response curves of densitometric readings versus amount of protein, thereby validating the quantification of the immunoblot.
Statistical Analysis
Statistical significance was assessed by Student's t-test. The Pearson product moment chi square test was used to assess the comparability of the diagnostic groups with respect to race (% Black), presence of Diabetes Mellitus, and absence of systemic diseases\ medications. Where appropriate, Fisher-type modifications were made to account for small sample size (Fisher, 1993) . Table I shows age, race, 3α-HSD activity, medications (ocular and non-ocular) and systemic diseases for all of the patients in both the nonglaucoma and POAG groups. A comparison of the two diagnostic groups is summarized in Table II . Statistical analysis of the composition of the two groups showed no significant (P 0n05)differences,therebyconfirmingthecomparability of the two diagnostic groups.
Results
Diagnostic Groups
PBL 3α-HSD Activity
The distribution of 3α-HSD activities in PBL from 17 POAG patients and 22 non-glaucoma controls is presented in Fig. 1 . Expressed in comparable units of activityp..., the POAG derived PBL contained a mean of 13n8p1n3 U as compared to 32n8p2n0 U for the control group. The 58 % decrease in 3α-HSD activity seen in the POAG derived PBL was statistically significant (P 0n001).
Since 15 of the 17 patients in the POAG group were receiving β adrenergic receptor antagonist (β-blocker) therapy, the putative role of these agents on PBL 3α-HSD activity was investigated. The non-glaucoma control group was divided into two groups, those with and without orally administered β-blocker therapy (for cardiovascular disease). The meanp... 3α-HSD activity for the control group taking β-blockers was 30n8p3n2 U as compared to 34n5p2n5 U for those not on this therapy. This difference was not significant (P l 0n35). When this control group on β-blocker therapy was further subdivided into β1-selective and non-selective agents, again there was no significant difference (P l 0n94) in activity (30n4p4n0 U and 31n4p6n7 U, respectively). It was of interest that one of these non-glaucoma control patients was receiving oral timolol maleate for treatment of cardiovascular disease. The 3α-HSD activity for this patient was 29n3 U, a value very similar to the mean of the non-glaucoma group.
T II
Comparison of diagnostic groups
The PBL 3α-HSD activity in the POAG group was also examined with respect to selectivity of β-blocker therapy. The meanp... 3α-HSD activity for the POAG patients taking β-1 selective was 12n9p 3n7 U as compared to 13n3p1n4 U for those on nonselective β-blockers. This difference was not significant (P l 0n91).
The possible effects of other ocular medications on PBL 3α-HSD activity in the POAG group were examined. Comparison of the enzyme activity of these patients with and without sympathomimetics (10n4p1n4 U vs. 15n2p1n7 U) or with and without parasympathomimetics (12n8p1n4 U vs. 16n1p3n0 U) also showed no significant differences (P l 0n11 and P l 0n27, respectively).
Immunoblot Analysis of 3α-HSD in PBL
Cytosolic preparations from the PBL of non-glaucoma and POAG patients were used for immunoblot analysis. Figure 2 shows a blot of the preparations F. 2. Immunoblot analysis of cytosolic preparations of lymphocytes from one non-glaucoma and two POAG patients. Lane 5, non-glaucoma patient (75 µg) ; lanes 6-7, POAG patients (100, 75 µg) ; lane 8, cytosol (60 µg protein) from human liver. Lanes 5-8, Protein-A purified anti 3α-HSD antibody. Lanes 1-4, same protein as in lanes 5-8, but probed with Protein-A purified preimmune serum.
from one non-glaucoma and two separate POAG patients. Protein-A purified anti-human 3α-HSD antibody reacted with a single major protein in the POAG (lanes 6 and 7) and non-glaucoma (lane 5) PBL homogenates. These bands, as well as one from human hepatic cytosol (lane 8), correspond to a MW of approximately 38 000. This molecular weight value was previously reported for 3α-HSD isolated from various species including human liver Binstock et al., 1992) . Parallel experiments with Protein-A purified non-immune sera showed no reacting proteins (lane 1-4). Since this immunoblot revealed similar levels of 3α-HSD protein expression, despite a reduction in 3α-HSD activity, quantitative analysis of additional samples was carried out (see below). F. 3. 3α-HSD protein ( ) and enzymatic activity () (Meanp...) in peripheral blood lymphocytes from four non-glaucoma and four POAG patients. of 3α-HSD protein. Despite this three-fold difference in 3α-HSD enzyme activity, however, there was no corresponding change in 3α-HSD protein.
Quantification of 3α-HSD activity and protein in POAG and control cells
Discussion
The present study demonstrates a statistically significant (P 0n001) reduction ( 50 %) of 3α-HSD activity in PBL derived from POAG patients which was not related to antiglaucoma therapy. Although approximately 90 % of the POAG patients showed a substantial decrease in PBL 3α-HSD activity, two of the 17 had values (26n7 and 25n0) approaching the ' normal ' range. Since POAG is a heterogeneous disease, this finding is not surprising. A suitably stratified larger clinical study would more precisely determine the extent of this variation. In addition, several of the nonglaucoma control subjects had low levels of PBL 3α-HSD activity (Fig. 1) . Although these patients did not reveal any traditional risk factors associated with POAG, it remains to be seen whether or not these patients with develop the disease.
3α-HSD may have a role in the regulation of IOP since it catalyses the conversion of the glucocorticoid potentiating (ocularly hypertensive) cortisol metabolite 5β-DHF to the hypotensive 3α,5β-THF. This hypothesis is supported by many studies of the biological activities of these metabolites. In young rabbits, topical application of 5β-DHF potentiated threshold levels of dexamethasone causing both the nuclear translocation of the glucocorticoid receptor of the iris-ciliary body (Weinstein et al., 1993) and the elevation of the IOP . 5β-DHF was also found to potentiate the glucocorticoid induced increase in collagen synthesis in explants of the outflow region of the rabbit eye (Southren et al., 1986) . In addition, 3α,5β-THF, a product of 3α-HSD, has been shown to be hypotensive in rabbits made ocularly hypertensive with glucocorticoids (Southren et al., 1987 ; Clark et al., 1994) and in patients with POAG (Southren et al., 1994) . 3,5β-THF has also recently been reported to antagonize the dexamethasone-induced cross-linked actin network formation (Clark et al., 1993 ; McCartney et al., 1994) and protein expression (Kawase et al., 1994) in HTM cell cultures, thereby providing a means by which 3α,5β-THF may alter outflow facility.
The results of the present study indicate that for many patients, POAG is associated with decreased PBL 3α-HSD activity. We hypothesize that a similar reduction in 3α-HSD activity in ocular tissue is responsible, in part, for the ocular hypertension and steroid sensitivity characteristic of these patients : the decreased 3α-HSD activity results in decreased conversion of 5β-DHF to 3α,5β-THF. The accumulation of 5β-DHF could lead to ocular hypertension and steroid sensitivity by potentiating endogenous and exogenous glucocorticoids. The concomitant decrease in the formation of the ocularly hypotensive 3α,5β-THF would augment these effects.
It is of interest that HTM cells derived from POAG patients showed an increase in cortisol-∆%-reductase activity and a decrease in 3α-HSD activity, while PBL showed only the latter change. The reasons for this are not known. Since 3α-HSD metabolizes many substrates, it remains to be determined whether the POAG-associated decrease of this enzyme results in other abnormalities.
Despite the POAG-related decrease in PBL 3α-HSD activity, these cells showed no change in the amount or molecular weight of the enzyme. The decrease in 3α-HSD activity, therefore, may be due to the presence of an intracellular inhibitor, post-translational modification, or a mutation in the 3α-HSD gene. Further experiments are required to distinguish between these and other possibilities. Nonetheless, the decreased 3α-HSD activity in the readily obtainable PBL may serve as a marker for POAG or those at risk for developing the disease.
